MARKET

RNXT

RNXT

Renovorx Inc
NASDAQ
1.105
-0.085
-7.14%
Opening 13:44 11/06 EST
OPEN
1.050
PREV CLOSE
1.190
HIGH
1.205
LOW
0.8800
VOLUME
1.43M
TURNOVER
--
52 WEEK HIGH
2.590
52 WEEK LOW
0.7006
MARKET CAP
49.87M
P/E (TTM)
-3.5214
1D
5D
1M
3M
1Y
5Y
1D
RenovoRx GAAP EPS of -$0.08 misses by $0.02, revenue of $1.07M beats by $0.01M
Seeking Alpha · 13h ago
RenovoRx backs FY26 revenue view $3.75M-$4.25M, consensus $3.87M
TipRanks · 23h ago
Press Release: RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million
Dow Jones · 1d ago
Press Release: RenovoRx Reports Record Third -2-
Dow Jones · 1d ago
Weekly Report: what happened at RNXT last week (1026-1030)?
Weekly Report · 4d ago
Weekly Report: what happened at RNXT last week (1019-1023)?
Weekly Report · 10/26 10:23
Weekly Report: what happened at RNXT last week (1012-1016)?
Weekly Report · 10/19 10:23
Weekly Report: what happened at RNXT last week (1005-1009)?
Weekly Report · 10/12 10:29
More
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.

Webull offers RenovoRx Inc stock information, including NASDAQ: RNXT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNXT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNXT stock methods without spending real money on the virtual paper trading platform.